

We retain **BUY** on steep price correction, and cut our TP to Rs675/sh (30x Sep-26 EPS). Aarti has posted sequential improvement in EBITDA over the past four quarters, led by demand recovery in discretionary spends like textiles, dyes, pigments, polymers, etc, and strong contribution from the energy business (led by a single product—MMA). However, it withdrew its FY25 EBITDA guidance of Rs14.5-17bn after the Q1 results, due to i) deferral in agro chemicals market recovery, ii) volatility in the energy business, iii) Chinese dumping leading to pricing pressure. We believe this view is largely owing to lower than expected volumes in MMA due to near-term macro volatility (August exports data shows 70% decline in MMA volume). We build-in Rs12.5/16.4/18.8bn (vs Rs14.6/19/22bn) EBITDA for FY25/26/27E, to factor in the margin volatility.

Aarti Industries: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	66,186	63,720	77,447	94,578	106,805
EBITDA	10,890	9,760	12,545	16,400	18,758
Adj. PAT	5,453	4,160	4,742	7,126	8,931
Adj. EPS (Rs)	15.1	11.5	13.1	19.7	24.7
EBITDA margin (%)	16.5	15.3	16.2	17.3	17.6
EBITDA growth (%)	0.0	(10.4)	28.5	30.7	14.4
Adj. EPS growth (%)	(17.1)	(23.7)	14.0	50.3	25.3
RoE (%)	11.6	8.1	8.6	11.8	13.2
RoIC (%)	11.6	9.4	9.0	11.0	12.2
P/E (x)	38.1	49.9	43.8	29.1	23.3
EV/EBITDA (x)	21.5	24.4	19.7	15.1	12.9
P/B (x)	4.2	3.9	3.6	3.3	2.9
FCFF yield (%)	(0.1)	(0.4)	(2.3)	0.7	4.0

Source: Company, Emkay Research

Mono Methyl Aniline (MMA) volumes to witness seasonality

The Energy business has now become relatively large for Aarti (~35-40%, based on our calculations), led by strong volumes from MMA. Management highlighted that this business is bringing additional volatility to the business performance, as it is linked to external factors like crude, gasoline cracks, and naphtha cracks, which have their own element of volatility. MMA has strong long-term potential to scale up volumes, as it a preferred octane booster in terms of characteristics and is competing with MTBE on price. Company is doing sampling for this octane booster and, as the end use horizon expands, volumes could be scaled up exponentially. Once product acceptance improves, this could contribute significantly to achieving the EBITDA targets envisaged by the company.

Agrochem recovery to push back by a Quarter

Aarti has been witnessing positive demand momentum in key end-use applications like pharma, polymers, additives, dyes, and pigments. However, in agrochemicals, demand recovery could be pushed back by a Quarter as there are only small green shoots of demand recovery as of now. Most global MNCs operating in the agchem space have guided for recovery from CY25; hence we believe Q4 should be better vs entire H2. Indian agrochemical companies are guiding for recovery from H2, but we believe this would be pushed back by a Quarter.

Overall volume growth to remain strong for FY25

Company maintained its volume growth guidance of 20-30%, but highlighted that pressure on margins persists. This is mostly owing to Chinese competition, which continues to dump products in global markets due to their domestic overcapacity situation. Volume growth will largely be led by improvement in utilization of existing capacities and commissioning of new nitro-toluene capacities. Management maintained its mid-to-long-term target of delivering 20-25% EBITDA CAGR over the next 5 years (2.5-3x growth on the FY24 base).

Target Price – 12M	Sep-25
Change in TP (%)	(15.6)
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	17.7
CMP (20-Sep-24) (Rs)	573.8

Stock Data	Ticker
52-week High (Rs)	770
52-week Low (Rs)	438
Shares outstanding (mn)	362.5
Market-cap (Rs bn)	208
Market-cap (USD mn)	2,489
Net-debt, FY25E (Rs mn)	38,984
ADTV-3M (mn shares)	2
ADTV-3M (Rs mn)	1,338.0
ADTV-3M (USD mn)	16.0
Free float (%)	-
Nifty-50	25,791
INR/USD	83.6
Shareholding, Jun-24	
Promoters (%)	43.2
FPIs/MFs (%)	10.6/18.6

Price Performance

(%)	1M	3M	12M
Absolute	(7.7)	(19.5)	13.0
Rel. to Nifty	(11.6)	(26.4)	(12.8)

1-Year share price trend (Rs)



Meet Vora

meet.vora@emkayglobal.com
+91 22 6624 2474

Meet Gada

meet.gada@emkayglobal.com
+91 22 6612 1235

Investment Thesis

Aarti's technical capabilities, low-cost manufacturing edge, willingness to invest, and consistently strengthening relationships with customers have helped the company grow its EBITDA ~12x over FY07-23. Aarti is among the most scalable chemical companies in India, given: i) its presence across a wide range of products – from basic to specialty, having diverse end-use applications; ii) integrated manufacturing leading to cost efficiencies and supply chains independent of China; and iii) favorable macro factors like depreciation of the INR versus RMB, import substitution, and 'China+1'.


Aarti's first-generation technocrat promoters built a global scale benzene derivatives business, and the second generation is now scaling up benzene & toluene derivatives. We expect mono methyl aniline (MMA) and methyl ethyl aniline (MEA) to be significantly large and scalable products for Aarti over the next few years. While the core portfolio is seeing relatively subdued demand currently, we believe the core portfolio of Para Di Chloro Benzene (PDCB), Para Nitro Chloro Benzene (PNCB), and other products within the aniline chain will start delivering significant delta to the overall EBITDA of the company, once demand recovers.

The company is well-positioned for growth in coming years, supported by its low-cost manufacturing advantage and relationships with global customers. Expansion of existing value chains and entering newer value chains will aid earnings momentum. Once these value chains are established, they will largely become a cash cow, and the next leg of growth will be driven by establishing universal MPP and value-added products. Moreover, entering more downstream products will lead to margin expansion and improve the quality of earnings.

Generally in high-growth chemical companies, a large part of the OCF is reinvested in capex; thus, there is very low FCF generation. We believe such companies are in the midst of an investment cycle seeing strong growth opportunities. Similarly, Aarti has undergone capex of ~Rs10-12bn in asset replacement, refurbishment, etc, as these plants were >20 years old and required refurbishment to enhance their useful lives. At the same time, the first long-term contract with capex of Rs8bn is lying in the gross block but not contributing to revenue. We believe a large part of this non-revenue generating capex is largely behind and, because the company is at the early phase of this replacement capex cycle, return ratios will optically look lower for it. However, going forward, return ratios are expected to improve on account of ramp up in existing value chains and long-term contracts.


A large part of the capex spent in the last five years has not contributed to Aarti's EBITDA due to i) cancellation of the first long-term contract, ii) spends on asset refurbishment/replacement, which are non-revenue generating, and iii) availability issues in nitric acid hindering volume growth. After a stagnant EBITDA growth over FY19-23, Aarti is now poised for a sharp EBITDA growth, along with RoCE improvement. We expect Aarti's revenue/EBITDA/PAT to register ~19%/24%/29% CAGR over FY24-27E. We believe Aarti is well poised for demand recovery in the chemicals space, once inventory destocking is over, with multiple tailwinds favoring its businesses. Also, we expect Aarti to gradually ramp up its EBITDA over the next few quarters, followed by contribution from the chlorotoluene chain from FY26E. We maintain BUY on Aarti, while revising down our target price to Rs675/share (from Rs800 earlier), valuing the stock at 30x its Sep-26E EPS, as the growth is largely back ended for FY26-27E.

Exhibit 1: Toluene chain to start ramping up sequentially, followed by rebound in the benzene chain




Source: Company, Emkay Research

Exhibit 2: Adj Gross Block/EBITDA to start improving, once demand recovers; to reach 22-25% at peak by FY27E/28E




Source: Company, Emkay Research; Note: *Gross Block adjusted for first long-term contract and replacement/refurbishment capex to the tune of Rs20bn; #FY20-22 contains pharma business EBITDA of ~Rs1.5-2bn; the pharma business has now been demerged

Exhibit 3: Brent-Naphtha cracks reducing difference in naphtha toward gasoline...




Source: Bloomberg, Emkay Research

Exhibit 4: ...supplemented by improving Ethylene-Naphtha spreads



Source: Bloomberg, Emkay Research


Exhibit 5: Revenue CAGR to clock at 19% over FY24-27E



Source: Company, Emkay Research

Revenue growth will be driven by recovery in the core portfolio, nitrotoluene expansion, and contribution from long-term contracts


Exhibit 6: Volume recovery, coupled with higher operating leverage, will lead to EBITDA growth



We build-in marginally higher margins, as operating leverage will kick-in once volumes see growth

Source: Company, Emkay Research


Exhibit 7: Company to generate enough OCF after the end of the capex cycle in FY25-26E



Capex to be funded by a mix of debt and internal accruals; debt to peak by FY26E

Source: Company, Emkay Research

Exhibit 8: Return ratios to rebound with focus on capacity utilization




Source: Company, Emkay Research

Exhibit 9: Specialty Chemicals companies – Peer valuations, a comparison

Peer (Domestic)	Ratings	P/E (x)			EV/E (x)			RoE (%)		
		FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
SRF	ADD	42	31	26	24	19	17	14	17	17
PI Industries	REDUCE	42	37	33	28	24	21	18	17	16
Gujarat Fluorochemicals	SELL	74	50	40	29	21	17	10	14	15
Deepak Nitrite	ADD	46	36	33	33	33	26	16	18	17
Aarti Industries	BUY	44	29	23	20	15	13	9	12	13
Navin Fluorine International	REDUCE	48	36	31	35	26	23	14	16	16
Anupam Rasayan India *	ADD	49	27	20	25	16	13	6	10	13
Epigral	BUY	27	20	18	14	11	10	23	24	22
Tata Chemicals	NR	33	23	22	13	11	10	4	5	5
Atul	NR	46	35	28	25	20	17	9	11	12
Vinati Organics	NR	50	38	37	33	26	23	16	19	18
Clean Science & Technology	NR	54	42	29	38	30	21	23	24	28
Fine Organic Industries	NR	37	34	30	27	24	22	21	19	19
Aether Industries	NR	85	58	37	54	37	23	7	10	13
Jubilant Ingrevia	NR	45	32	25	23	17	14	9	12	14
Archean Chemical Industries	NR	23	16	12	15	10	8	20	24	24
Deepak Fertilisers & Petrochem	NR	18	14	10	9	8	6	9	9	17
Laxmi Organic Industries	NR	52	42	29	24	19	14	8	10	13
Sudarshan Chemical Industries	NR	38	28	24	18	15	13	15	18	18
Neogen Chemicals	NR	93	62	46	43	28	16	8	11	14


Source: Bloomberg, Emkay Research; Note: *Standalone

Exhibit 10: One-year forward P/E



Source: Bloomberg, Emkay Research

Exhibit 11: One-year forward EV/EBITDA



Source: Bloomberg, Emkay Research

Aarti Industries: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	66,186	63,720	77,447	94,578	106,805
Revenue growth (%)	6.1	(3.7)	21.5	22.1	12.9
EBITDA	10,890	9,760	12,545	16,400	18,758
EBITDA growth (%)	0.0	(10.4)	28.5	30.7	14.4
Depreciation & Amortization	3,105	3,780	4,550	5,272	5,689
EBIT	7,786	5,980	7,995	11,128	13,069
EBIT growth (%)	(7.6)	(23.2)	33.7	39.2	17.4
Other operating income	0	0	0	0	0
Other income	9	80	80	80	80
Financial expense	1,683	2,110	2,497	2,824	2,642
PBT	6,111	3,950	5,579	8,384	10,507
Extraordinary items	0	0	0	0	0
Taxes	659	(210)	837	1,258	1,576
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	5,453	4,160	4,742	7,126	8,931
PAT growth (%)	(17.1)	(23.7)	14.0	50.3	25.3
Adjusted PAT	5,453	4,160	4,742	7,126	8,931
Diluted EPS (Rs)	15.1	11.5	13.1	19.7	24.7
Diluted EPS growth (%)	(17.1)	(23.7)	14.0	50.3	25.3
DPS (Rs)	2.5	1.5	1.3	2.0	2.5
Dividend payout (%)	16.6	13.0	10.0	10.0	10.0
EBITDA margin (%)	16.5	15.3	16.2	17.3	17.6
EBIT margin (%)	11.8	9.4	10.3	11.8	12.2
Effective tax rate (%)	10.8	(5.3)	15.0	15.0	15.0
NOPLAT (pre-IndAS)	6,946	6,298	6,796	9,459	11,109
Shares outstanding (mn)	362.0	362.0	362.0	362.0	362.0

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
PBT	6,111	3,950	5,579	8,384	10,507
Others (non-cash items)	3,105	3,780	4,550	5,272	5,689
Taxes paid	(909)	(910)	(837)	(1,258)	(1,576)
Change in NWC	3,224	1,768	(1,262)	(3,422)	(2,443)
Operating cash flow	13,098	12,040	10,446	11,720	14,739
Capital expenditure	(13,268)	(12,988)	(16,000)	(10,000)	(5,000)
Acquisition of business	109	(58)	0	0	0
Interest & dividend income	9	80	80	80	80
Investing cash flow	(13,298)	(13,100)	(15,920)	(9,920)	(4,920)
Equity raised/(repaid)	3	0	0	0	0
Debt raised/(repaid)	3,061	3,100	7,999	1,410	(6,651)
Payment of lease liabilities	0	0	0	0	0
Interest paid	(1,683)	(2,110)	(2,497)	(2,824)	(2,642)
Dividend paid (incl tax)	(906)	(540)	(474)	(713)	(893)
Others	(3)	(100)	0	0	0
Financing cash flow	472	350	5,028	(2,127)	(10,186)
Net chg in Cash	272	(710)	(445)	(326)	(367)
OCF	13,098	12,040	10,446	11,720	14,739
Adj. OCF (w/o NWC chg.)	16,322	13,808	9,184	8,298	12,296
FCFF	(170)	(948)	(5,554)	1,720	9,739
FCFE	(1,844)	(2,978)	(7,970)	(1,024)	7,177
OCF/EBITDA (%)	120.3	123.4	83.3	71.5	78.6
FCFE/PAT (%)	(33.8)	(71.6)	(168.1)	(14.4)	80.4
FCFF/NOPLAT (%)	(2.4)	(15.1)	(81.7)	18.2	87.7

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	1,813	1,813	1,813	1,813	1,813
Reserves & Surplus	47,388	51,080	55,348	61,762	69,800
Net worth	49,201	52,893	57,161	63,574	71,612
Minority interests	7	7	7	7	7
Deferred tax liability (net)	(528)	(1,440)	(1,440)	(1,440)	(1,440)
Total debt	28,740	31,840	39,839	41,249	34,598
Total liabilities & equity	77,421	83,300	95,567	103,391	104,777
Net tangible fixed assets	48,287	55,875	67,325	72,053	71,364
Net intangible assets	322	615	615	615	615
Net ROU assets	303	530	530	530	530
Capital WIP	10,962	12,290	12,290	12,290	12,290
Goodwill	0	0	0	0	0
Investments [JV/Associates]	172	230	230	230	230
Cash & equivalents	2,007	1,300	855	528	161
Current assets (ex-cash)	23,531	24,410	27,564	33,435	37,625
Current Liab. & Prov.	7,861	11,420	13,311	15,760	17,508
NWC (ex-cash)	15,670	12,990	14,252	17,674	20,117
Total assets	77,421	83,300	95,567	103,391	104,777
Net debt	26,733	30,540	38,984	40,721	34,437
Capital employed	77,421	83,300	95,567	103,391	104,777
Invested capital	64,279	69,480	82,192	90,342	92,096
BVPS (Rs)	135.9	146.1	157.9	175.6	197.8
Net Debt/Equity (x)	0.5	0.6	0.7	0.6	0.5
Net Debt/EBITDA (x)	2.5	3.1	3.1	2.5	1.8
Interest coverage (x)	0.2	0.3	0.3	0.3	0.2
RoCE (%)	10.5	7.5	9.0	11.3	12.6

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	38.1	49.9	43.8	29.1	23.3
P/CE(x)	24.3	26.2	22.4	16.8	14.2
P/B (x)	4.2	3.9	3.6	3.3	2.9
EV/Sales (x)	3.5	3.7	3.2	2.6	2.3
EV/EBITDA (x)	21.5	24.4	19.7	15.1	12.9
EV/EBIT(x)	30.1	39.8	30.9	22.3	18.5
EV/IC (x)	3.6	3.4	3.0	2.7	2.6
FCFF yield (%)	(0.1)	(0.4)	(2.3)	0.7	4.0
FCFE yield (%)	(0.9)	(1.4)	(3.8)	(0.5)	3.5
Dividend yield (%)	0.4	0.3	0.2	0.3	0.4
DuPont-RoE split					
Net profit margin (%)	8.2	6.5	6.1	7.5	8.4
Total asset turnover (x)	0.9	0.8	0.9	1.0	1.0
Assets/Equity (x)	1.6	1.6	1.6	1.6	1.5
RoE (%)	11.6	8.1	8.6	11.8	13.2
DuPont-RoIC					
NOPLAT margin (%)	10.5	9.9	8.8	10.0	10.4
IC turnover (x)	1.1	1.0	1.0	1.1	1.2
RoIC (%)	11.6	9.4	9.0	11.0	12.2
Operating metrics					
Core NWC days	86.4	74.4	67.2	68.2	68.7
Total NWC days	86.4	74.4	67.2	68.2	68.7
Fixed asset turnover	1.2	0.9	0.9	1.0	1.0
Opex-to-revenue (%)	25.5	23.8	23.3	23.0	23.0

Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
27-Aug-24	640	800	Buy	Meet Vora
13-Aug-24	621	800	Buy	Meet Vora
14-Jul-24	706	800	Buy	Meet Vora
07-Jun-24	635	800	Buy	Meet Vora
13-May-24	669	800	Buy	Meet Vora
07-Apr-24	696	750	Buy	Meet Vora
26-Feb-24	672	750	Buy	Meet Vora
09-Feb-24	663	750	Buy	Meet Vora
18-Jan-24	612	750	Buy	Meet Vora

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of September 24, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report
Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of September 24, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the September 24, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.